Vertex Pharmaceuticals Inc. / Semma Therapeutics Inc.
2019 · Acquisition/Merger · $950M · Complete
Announcement Sentiment
83
Strongly positive
Outcome Score
86
Worked — the deal delivered on its rationale.
Vertex Pharmaceuticals acquired Semma Therapeutics for $950 million in cash, gaining stem cell-derived human islet cell therapy technology for type 1 diabetes, including methods for producing functional pancreatic beta cells and a proprietary cell encapsulation device enabling implantation without chronic immunosuppression.